News | Cardiac Diagnostics | April 25, 2017

Body Weight Fluctuations Linked to More Deaths in People with Coronary Artery Disease

Study finds group with largest weight changes experienced over 100 percent more strokes, heart attacks and deaths than those with smallest weight changes

Body Weight Fluctuations Linked to More Deaths in People with Coronary Artery Disease

April 25, 2017 — Repeated cycles of weight loss and gain may be linked to higher risk for stroke, heart attack and death in people with pre-existing coronary artery disease, according to a study published online in the New England Journal of Medicine.

Led by researchers at NYU Langone Medical Center, the study was the first to measure the effect of “weight cycling” on health outcomes in people with pre-existing heart disease. People with the largest weight changes were found to experience 136 percent more strokes, 117 percent more heart attacks and 124 percent more deaths than those with the smallest shifts in weight. Those in the high-fluctuation group had weight changes as large as 3.9 kilograms (or roughly 8.6 pounds), while weight varied by around 0.9 kilograms (just under 2 pounds) in the group with the smallest shifts in weight.

“Our findings suggest that we need to be concerned about weight fluctuation in this group that is already at high risk due to coronary disease,” said lead study author Sripal Bangalore, M.D., director of the cardiovascular outcomes group in the Cardiovascular Clinical Research Center at NYU Langone.

“Even though this analysis was not designed to find out the causes of increased risk with body weight fluctuations, we need to examine how we can help Americans keep weight off, rather than having it go up and down,” said Bangalore, an associate professor of medicine in the Leon H. Charney Division of Cardiology.

The research team reviewed data on 9,509 men and women with coronary artery disease who participated in the Treating to New Targets trial, which was originally concluded in 2005. Study participants were between the ages of 35 and 75. All had coronary artery disease, high cholesterol levels, and some history of heart problems. Half were being treated with cholesterol-lowering drugs in intensive (versus standard) doses to see if this resulted in fewer deaths. All were monitored for a median of 4.7 years. The analysis linked shifts in body weight to statistically significant differences in outcomes only in people who were overweight or obese at the beginning of the study, but not for people who started with normal weight. Body weight changes were also strongly linked to an increase in newly diagnosed diabetes, and associations persisted regardless of a person’s average body weight and traditional risk factors for heart disease.

The researchers caution that their re-analysis does not show a cause-and-effect relationship between weight cycling and poor outcomes, but only an association. The authors also recognize that they were unable to tell if people lost weight intentionally, unintentionally or due to illness, or if any eventual heart problems resulted directly from the weight loss, change in weight or illness.

Bangalore hopes that the current findings will lead to further study of weight fluctuation in people with coronary artery disease and to the development of related practice guidelines once all the evidence is in. In the United States, more than 36 percent of American adults are obese, according to the Centers for Disease Control and Prevention. Additionally, about half of Americans report they are trying to lose weight, and weight cycling is frequent. Obesity is known to increase the risk for high blood pressure, high cholesterol, and diabetes, as well as for coronary artery disease.

Besides Bangalore, other researchers involved in the study were Rana Fayyad and David DeMicco from Pfizer Inc.; Rachel Laskey from THOR Specialties; Frank Messerli at the University Hospital Bern, Switzerland; and David Waters at San Francisco General Hospital.

For more information: www.nejm.org

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init